{"title":"多发性风湿性关节炎患者使用托珠单抗成功治疗侵袭性 AA 淀粉样变性。","authors":"Nuh Atas, Ali Rıza Çalışkan, Ayşenur Akatlı","doi":"10.1093/mrcr/rxae050","DOIUrl":null,"url":null,"abstract":"<p><p>Polymyalgia rheumatic (PMR) associated amyloidosis is an extremely rare condition that can be rapidly progressive with high morbidity and mortality and management is challenging. Tocilizumab is a monoclonal anti-IL-6 receptor antibody, which is in the therapeutic arsenal of PMR. The efficiency of tocilizumab in improvement of PMR activity score and decreasing steroid dose is well-established, while efficiency in PMR-associated amyloidosis has not been published. Herein, we reported a PMR patient with amyloid A amyloidosis who was treated effectively with tocilizumab.</p>","PeriodicalId":94146,"journal":{"name":"Modern rheumatology case reports","volume":" ","pages":"214-217"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful treatment of aggressive AA amyloidosis with tocilizumab in a patient with polymyalgia rheumatica.\",\"authors\":\"Nuh Atas, Ali Rıza Çalışkan, Ayşenur Akatlı\",\"doi\":\"10.1093/mrcr/rxae050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Polymyalgia rheumatic (PMR) associated amyloidosis is an extremely rare condition that can be rapidly progressive with high morbidity and mortality and management is challenging. Tocilizumab is a monoclonal anti-IL-6 receptor antibody, which is in the therapeutic arsenal of PMR. The efficiency of tocilizumab in improvement of PMR activity score and decreasing steroid dose is well-established, while efficiency in PMR-associated amyloidosis has not been published. Herein, we reported a PMR patient with amyloid A amyloidosis who was treated effectively with tocilizumab.</p>\",\"PeriodicalId\":94146,\"journal\":{\"name\":\"Modern rheumatology case reports\",\"volume\":\" \",\"pages\":\"214-217\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern rheumatology case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/mrcr/rxae050\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern rheumatology case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/mrcr/rxae050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
多发性风湿痛伴淀粉样变性是一种极为罕见的疾病，可迅速进展，发病率和死亡率高，治疗难度很大。Tocilizumab 是一种抗 IL-6 受体的单克隆抗体，是多发性风湿痛的治疗药物之一。托西珠单抗在改善多发性风湿痛活动评分和减少类固醇剂量方面的疗效已得到公认，但在多发性风湿痛相关淀粉样变性中的疗效尚未公布。在此，我们报告了一名合并 AA 淀粉样变性的多发性风湿痛患者，该患者接受了托珠单抗的有效治疗。
Successful treatment of aggressive AA amyloidosis with tocilizumab in a patient with polymyalgia rheumatica.
Polymyalgia rheumatic (PMR) associated amyloidosis is an extremely rare condition that can be rapidly progressive with high morbidity and mortality and management is challenging. Tocilizumab is a monoclonal anti-IL-6 receptor antibody, which is in the therapeutic arsenal of PMR. The efficiency of tocilizumab in improvement of PMR activity score and decreasing steroid dose is well-established, while efficiency in PMR-associated amyloidosis has not been published. Herein, we reported a PMR patient with amyloid A amyloidosis who was treated effectively with tocilizumab.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
